Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: Importance of transcellular biosynthesis of cysteinyl-leukotrienes

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 1, 1996, Pages 335-341

  Rossoni, G ^a   Sala, A ^a   Berti, F ^a   Testa, T ^a   Buccellati, C ^a   Molta, C ^a,d   Muller Peddinghaus, R ^b   Maclouf, J ^c   Folco, G C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b BAYER AG   (Germany)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Schering Plough   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; LEUKOTRIENE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CALCIMYCIN; CORONARY VESSELS; CREATINE KINASE; CYSTEINE; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HEART; HEART DISEASES; HUMANS; L-LACTATE DEHYDROGENASE; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEUTROPHILS; PEROXIDASE; QUINOLINES; RABBITS;

EID: 0029876318     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ANTOINE, C., LELLOUCHE, J. P., MACLOUF, J. AND PRADELLES, P.: Development of enzyme immunoassays for leukotrienes using acetylcholinesterase. Biochim. Biophys. Acta 1075: 162-168, 1991.
2. BAUMANN, G., RIESS, G., ERHARDT, W. D., FELIX, S. B., LUDWIG, L., BLÜMEL, G. AND BLÖMER, H.: Impaired beta-adrenergic stimulation in the uninvolved ventricle post-acute myocardial imfarction: Reversible defect due to excessive circulating catecholamine-induced decline in number and affinity of beta-receptors. Am. Heart J. 101: 569-581, 1981.
3. BERTI, F., ROSSONI, G., MAGNI, F., CARUSO, D., OMINI, C., PUGLISI, L. AND GALLI, G.: Non-steroidal antiinflammatory drugs aggravate acute myocardial schemia in perfused rabbit heart: A role for prostacyclin. J. Cardiovasc. Pharmacol. 12: 438-444, 1988.
4. CHAMBERS, D. E., PARKS, D. A., PATTERSON, G., ROY, R., MCCORD, J. M., YOSHIDA, S., PARMLEY, L. F. AND DOWNEY, J. M.: Xanthine oxidase as a source of free radical damage in myocardial ischemia. J. Mol. Cell. Cardiol. 17: 145-152, 1985.
5. CARRY, M., KORLEY, V., WILLERSON, J T , WEIGELT, L., FORD-HUTCHINSON, A. W. AND TAGARI, P.: Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 83: 230-236, 1992.
6. FEUERSTEIN, G.: Autonomic pharmacology of leukotrienes. J Auton. Pharmacol. 5: 149-168, 1985.
7. FRUCHTMANN, R., MOHRS, K.-H., HATZELMANN, A., RADDATZ, S., FUGMANN, B., JUNGE, B., HORSTMANN, H. AND MULLER-PEDDINGHAUS, R.: In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 38: 188-195, 1993.
8. GARDINER, P J , CUTHBERT, N. J., FRANCIS, H. P., FITZGERALD, M. F., THOMPSON, A. M., CARPENTER, T. G., PATEL, U. P., NEWTON, B. B., MOHRS, K., MULLER-PEDDINGHAUS, R. AND TAYLOR, W. A.: Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY X1005. Eur. J. Pharmacol. 258: 95-102, 1994.
9. GILLESPIE, T. A. AND SOBEL, B E.: A rationale for therapy of acute myocardial infarction: Limitation of infarct size. Adv Intern. Med. 22: 319-353, 1977.
10. 4 transfer. Blood 72: 1687-1692, 1988.
11. 4 receptors does not limit canine myocardial infarct size. J. Pharmacol. Exp. Ther. 253: 58-65, 1990.
12. HATZELMANN, A., FRUCHTMANN, R., MOHRS, K. H., RADDATZ, S. AND MÜLLER-PEDDINGHAUS, R.: Mode of action of the new selective leukotriene synthesis inhibitor BAY X1005 {(R)-2-[4-(quinolin-2-YL-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds. Biochem. Pharmacol. 45: 101-111, 1993.
13. HATZELMANN, A., GOOSSENS, J., FRUCHTMANN, R., MOHRS, K.-H., RADDATZ, S. AND MULLER-PEDDINGHAUS, R.: Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system. Implications for the function of 5-lipoxygenase activating protein. Biochem. Pharmacol. 47: 2259-2268, 1994a.
14. 4. Biochem. Pharmacol. 48: 31-39, 1994b.
15. HOCK, C. E., BECK, L. D. AND PAPA, L. A.: Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion. Cardiovasc. Res. 26: 1206-1211, 1992.
16. KIRLIN, P. C., ROMSON, J. L., PITT, B., ABRAMS, G. D., SCHORK, M. A. AND LUCCHESI, B. R.: Ibuprofen-mediated infarct size reduction: Effects on regional myocardial infarction Am. J. Cardiol. 50: 849-856, 1982.
17. KLONER, R A., GIACOMELLI, F., ALKER, K. J., HALE, S. L., MATTHEWS, R. AND BELLOWS, S.: Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation 84: 1758-1772, 1991.
18. 4 by human platelets. J. Biol. Chem. 263: 174-181, 1988.
19. 4: A potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 217: 841-843, 1982.
20. MULLANE, K., HATALA, M. A., KRAEMER, R., SESSA, W. AND WESTLIN, W.: Myocardial salvage induced by REV-5901: An inhibitor and antagonist of the leukotrienes. J. Cardiovasc. Pharmacol. 10: 398-406, 1987.
21. MÜLLER-PEDDINGHAUS, R , KOHLSDORFER, C., THEISEN-POPP, P., FRUCHTMANN, R., PERZBORN, E., BECKERMANN, B., BUHNER, K., AHR, H. J AND MOHRS, K. H.: BAY X1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Ther. 267: 51-55, 1993a.
22. MULLER-PEDDINGHAUS, R., FRUCHTMANN, R., AHR, H. J., BECKERMANN, B., BUHNER, K., FUGMANN, B., JUNGE, B., MATZKE, M., KOHLSDORFER, C., RADDTZ, S., THEISEN-POPP, P. AND MOHRS, K. H.: BAY X1005, a new selective inhibitor of leukotriene synthesis: Pharmacology and pharmacokinetics. J. Lipid Mediators 6: 245-248, 1993b.
23. PRADELLES, P., GRASSI, J. AND MACLOUF, J.: Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: An alternative to radioimmunoassay. Anal. Chem. 57: 1170-1173, 1985.
24. ROBERTS, R.: Diagnostic assessment of myocardial infarction based on lactate dehydrogenase and creatine kinase isoenzymes. Heart Lung 10: 486-506, 1981.
25. ROSALKI, S B.: An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med. 69: 697-703, 1967.
26. ROUZER, C. A., FORD-HUTCHINSON, A. W , MORTON, H. E. AND GILLARD, J. W.: MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem. 265: 1436-1442, 1990.
27. SALA, A., ROSSONI, G., BUCCELLATI, C., BERTI, F., FOLCO, G. C. AND MACLOUF, J.: Formation of sulphidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit. Br. J. Pharmacol. 110: 1206-1212, 1993.
28. SCHIERWAGEN, C., BYLUND-FELLENIUS, A. C. AND LUNDBERG, C.: Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Methods 23: 179-186, 1990.
29. SNEDECOR, G. W. AND COCHRAN, W. G.: Statistical Methods, Iowa State University Press, Ames, LA, 1989.
30. 4: Inflammatory agonists that induce PAF synthesis and endothelial cell-dependent neutrophil adhesion. In Advances in Rheumatology and Inflammation. vol. 2: Leukotrienes and Vascular Phenomena of Inflammation Related to Rheumatoid Arthritis, ed. by R. Muller-Peddinghaus, pp. 49-58, Eular Publ., Basel, 1992.